Personalized Therapy of Hormone-Responsive Breast Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (20 October 2024) | Viewed by 4069
Special Issue Editors
Interests: pharmacology of anti-cancer drugs; pharmacogenetics of anti-estrogens; ex vivo models of human tumors (tissue culture, organoids) to investigate anti-cancer drugs
Special Issue Information
Dear Colleagues,
Breast cancer is the leading malignancy worldwide with 2.26 million new cases diagnosed in 2020 and an increasing incidence. Approximately 70–80% of tumors are hormone-receptor positive and therefore are considered for endocrine therapy. Treatment modalities depend on patients’ menopausal status, tumor stage, performance status, and tumor markers. More than 30% of patients in the adjuvant and even more in advanced stages suffer from disease progress due to intrinsic or acquired resistance against endocrine therapy. To overcome treatment failures, including drug discontinuation due to drug-induced toxicity, better prognostic markers—but also new treatment opportunities—are needed.
This Special Issue will focus on basic, translational, and clinical studies aiming to improve endocrine therapy by the identification of new and better predictors for personalized treatment decisions and therapeutic approaches, including the selection of multimodal targets, the use of bioinformatic prediction tools, and both mechanistic and clinical investigations to overcome endocrine drug failure in breast cancer.
Dr. Thomas Mürdter
Dr. Werner Schroth
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hormone
- therapy
- breast cancer
- estrogens
- resistance
- combinational therapy
- anti-estrogens, kinase inhibitors
- checkpoint inhibitors
- chemotherapy
- in vitro models
- clinical trials
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
